Early Parkinson's Disease Phenotypes Tailored by Personality, Behavior, and Motor Symptoms.


Journal

Journal of Parkinson's disease
ISSN: 1877-718X
Titre abrégé: J Parkinsons Dis
Pays: Netherlands
ID NLM: 101567362

Informations de publication

Date de publication:
2022
Historique:
pubmed: 10 5 2022
medline: 14 7 2022
entrez: 9 5 2022
Statut: ppublish

Résumé

Previous studies described a parkinsonian personality characterized as rigid, introverted, and cautious; however, little is known about personality traits in de novo Parkinson's disease (PD) patients and their relationships with motor and neuropsychiatric symptoms. To investigate personality in de novo PD and explore its relationship with PD symptoms. Using Cloninger's biosocial model, we assessed personality in 193 de novo PD patients. Motor and non-motor symptoms were measured using several validated scales. Cluster analysis was conducted to investigate the interrelationship of personality traits, motor, and non-motor symptoms. PD patients showed low novelty seeking, high harm avoidance, and normal reward dependence and persistence scores. Harm avoidance was positively correlated with the severity of depression, anxiety, and apathy (rs = [0.435, 0.676], p < 0.001) and negatively correlated with quality of life (rs = -0.492, p < 0.001). Novelty seeking, reward dependence, and persistence were negatively correlated with apathy (rs = [-0.274, -0.375], p < 0.001). Classification of patients according to personality and PD symptoms revealed 3 distinct clusters: i) neuropsychiatric phenotype (with high harm avoidance and low novelty seeking, hypodopaminergic neuropsychiatric symptoms and higher impulsivity), ii) motor phenotype (with low novelty seeking and higher motor severity), iii) benign phenotype (with low harm avoidance and high novelty seeking, reward dependence, and persistence traits clustered with lower symptoms severity and low impulsivity). Personality in early PD patients allows us to recognize 3 patients' phenotypes. Identification of such subgroups may help to better understand their natural history. Their longitudinal follow-up will allow confirming whether some personality features might influence disease evolution and treatment.

Sections du résumé

BACKGROUND
Previous studies described a parkinsonian personality characterized as rigid, introverted, and cautious; however, little is known about personality traits in de novo Parkinson's disease (PD) patients and their relationships with motor and neuropsychiatric symptoms.
OBJECTIVE
To investigate personality in de novo PD and explore its relationship with PD symptoms.
METHODS
Using Cloninger's biosocial model, we assessed personality in 193 de novo PD patients. Motor and non-motor symptoms were measured using several validated scales. Cluster analysis was conducted to investigate the interrelationship of personality traits, motor, and non-motor symptoms.
RESULTS
PD patients showed low novelty seeking, high harm avoidance, and normal reward dependence and persistence scores. Harm avoidance was positively correlated with the severity of depression, anxiety, and apathy (rs = [0.435, 0.676], p < 0.001) and negatively correlated with quality of life (rs = -0.492, p < 0.001). Novelty seeking, reward dependence, and persistence were negatively correlated with apathy (rs = [-0.274, -0.375], p < 0.001). Classification of patients according to personality and PD symptoms revealed 3 distinct clusters: i) neuropsychiatric phenotype (with high harm avoidance and low novelty seeking, hypodopaminergic neuropsychiatric symptoms and higher impulsivity), ii) motor phenotype (with low novelty seeking and higher motor severity), iii) benign phenotype (with low harm avoidance and high novelty seeking, reward dependence, and persistence traits clustered with lower symptoms severity and low impulsivity).
CONCLUSION
Personality in early PD patients allows us to recognize 3 patients' phenotypes. Identification of such subgroups may help to better understand their natural history. Their longitudinal follow-up will allow confirming whether some personality features might influence disease evolution and treatment.

Identifiants

pubmed: 35527563
pii: JPD213070
doi: 10.3233/JPD-213070
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1665-1676

Auteurs

Bruna Meira (B)

Neurology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal.
Movement Disorders Center, Neurology, CHU Grenoble Alpes, Grenoble, France.

Eugénie Lhommée (E)

Movement Disorders Center, Neurology, CHU Grenoble Alpes, Grenoble, France.

Emmanuelle Schmitt (E)

Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.

Hélène Klinger (H)

Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Neurologie C, Centre Expert Parkinson, Lyon, France.
Univ Lyon, Université Claude Bernard Lyon 1, CNRS, Institut des Sciences Cognitives Marc Jeannerod, Bron, France.

Amélie Bichon (A)

Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.

Pierre Pélissier (P)

Movement Disorders Center, Neurology, CHU Grenoble Alpes, Grenoble, France.

Mathieu Anheim (M)

Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, (IGBMC), INSERM-U964/CNRS-UMR7104/, Université de Strasbourg, Illkirch, France.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Christine Tranchant (C)

Département de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Institut de Génétique et de Biologie Moléculaire et Cellulaire, (IGBMC), INSERM-U964/CNRS-UMR7104/, Université de Strasbourg, Illkirch, France.
Fédération de Médecine Translationnelle de Strasbourg (FMTS), Université de Strasbourg, Strasbourg, France.

Valérie Fraix (V)

Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.

Sara Meoni (S)

Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.

Franck Durif (F)

Université Clermont Auvergne, NPsy-Sydo, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand, France.

Jean-Luc Houeto (JL)

Service de Neurologie, Centre Expert Parkinson, CHU de Limoges, UMR1094 INSERM, Université de Limoges, Limoges, France.

Jean Philippe Azulay (JP)

Neurology and Pathology Department of the Movement, University Hospital of Marseille, Timone Hospital, Marseille, France.

Elena Moro (E)

Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.

Stéphane Thobois (S)

Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Neurologie C, Centre Expert Parkinson, Lyon, France.
Univ Lyon, Université Claude Bernard Lyon 1, CNRS, Institut des Sciences Cognitives Marc Jeannerod, Bron, France.

Paul Krack (P)

Department of Neurology, Inselspital, University Hospital Bern, Bern, Switzerland.

Anna Castrioto (A)

Université Grenoble Alpes, Inserm, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Grenoble, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH